文献速递细胞病理与分子病理

国际浆膜液细胞病理学报告系统在社区医院环境中的恶性风险评估及与其他研究的比较

Risk of malignancy assessment of the International System for Reporting Serous Fluid Cytopathology: Experience in a community hospital setting and comparison with other studies.
PubMed 文献 · Cancer Cytopathol · 2022-08-22

该研究在社区医院环境下回顾性应用国际浆膜液细胞病理学报告系统(ISRSFC)对446例腹膜积液和299例胸腔积液标本进行重新分类,计算各诊断类别的恶性风险(ROM)。结果显示腹膜积液ROM为ND 0.0%、NFM 1.8%、AUS 37.5%、SFM 83.3%、MAL 100.0%;胸腔积液ROM为ND 8.3%、NFM 1.2%、AUS 44.4%、SFM和MAL均为100.0%。作者认为各实验室应基于自身数据开展ROM分析。

要点

  • ISRSFC各诊断类别在社区医院中的ROM分布与已有研究总体一致。
  • AUS和SFM类别的ROM较高,需结合临床进一步明确。
  • 各实验室应建立自己的ISRSFC分层ROM数据。

核心结论

  • 已发表的ISRSFC重新分类研究之间存在显著异质性,提示各实验室应基于自身统计数据进行ROM分析。

研究设计与样本

  • 回顾性研究,经内部审查委员会批准,纳入三家社区医院12个月内的576例患者的446例腹膜积液标本和299例胸腔积液标本。
  • 按照ISRSFC对标本进行重新分类并计算各诊断类别的恶性风险(ROM)。

主要发现

  • 胸腔积液重新分类后:ND 18例(5.0%)、NFM 273例(76.0%)、AUS 18例(5.0%)、SFM 6例(1.7%)、MAL 44例(12.3%)。
  • 腹膜积液重新分类后:ND 11例(5.5%)、NFM 168例(77.1%)、AUS 9例(4.1%)、SFM 2例(0.9%)、MAL 27例(12.4%)。
  • 腹膜积液ROM:ND 0.0%、NFM 1.8%、AUS 37.5%、SFM 83.3%、MAL 100.0%。
  • 胸腔积液ROM:ND 8.3%、NFM 1.2%、AUS 44.4%、SFM和MAL均为100.0%。

关键数值与推荐

  • 腹膜积液ROM:ND 0.0%、NFM 1.8%、AUS 37.5%、SFM 83.3%、MAL 100.0%。
  • 胸腔积液ROM:ND 8.3%、NFM 1.2%、AUS 44.4%、SFM和MAL均为100.0%。

临床怎么用

  • 病理科可参照ISRSFC对浆膜液进行标准化分层报告,并基于本实验室数据计算各诊断类别的ROM。
  • 对AUS和SFM类别应结合临床和其他检查进一步评估恶性可能性。

局限性

  • 本研究为回顾性单地区社区医院研究,样本量有限,结果外推需谨慎。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The International System for Reporting Serous Fluid Cytopathology (ISRSFC) was published recently to provide standard reporting terminology for serous fluid. To date, several ISRSFC reclassification studies have reported a wide range of diagnostic category frequency and the associated risk of malignancy (ROM). Herein, the authors applied the ISRSFC to report pleural and peritoneal effusions retrospectively in a community hospital setting. METHODS: With Internal Review Board approval, 446 peritoneal effusion specimens and 299 pleural fluid specimens from 576 patients in three community hospitals over a 12-month period were reviewed and reclassified according to the ISRSFC. RESULTS: After reclassification, in pleural effusions, 18 (5.0%) were nondiagnostic (ND), 273 (76.0%) were negative for malignancy (NFM), 18 (5.0%) were atypia of undetermined significance (AUS), 6 (1.7%) were suspicious for malignancy (SFM), and 44 (12.3%) were malignant (MAL). In peritoneal effusions, after reclassification, 11 (5.5%) were ND, 168 (77.1%) were NFM, 9 (4.1%) were AUS, 2 (0.9%) were SFM, and 27 (12.4%) were MAL. The calculated ROM was 0.0% for ND, 1.8% for NFM, 37.5% for AUS, 83.3% for SFM, and 100.0% for MAL in peritoneal effusions; and the ROM was 8.3% for ND, 1.2% for NFM, 44.4% for AUS, and 100.0% for both SFM and MAL in pleural effusions. Further analysis demonstrated notable heterogeneity among published ISRSFC reclassification studies, although the overall ROMs did not differ significantly from the ISRSFC-determined ROMs (all p values were > .05 for mean ROM comparisons). CONCLUSIONS: The findings suggested the necessity for each laboratory to perform its own ROM analysis based on its statistics for ISRSFC-tiered classification terminology.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Sun T, Wang M, Wang H, et al. Risk of malignancy assessment of the International System for Reporting Serous Fluid Cytopathology: Experience in a community hospital setting and comparison with other studies. Cancer Cytopathol. 2022. PMID: 35994357. doi:10.1002/cncy.22638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。